Share page on LinkedIn

Decentralised & hybrid clinical trials

Patient focused research for better outcomes

With the rising cost and time to bring new drugs to market and more recently the pandemic outbreak, the demand for decentralised and hybrid trials has risen. These alternative trial models can range in shape and form to include digital health technologies, in-home clinical visits and remote monitoring.

Decentralised and hybrid clinical trials

Decentralised and hybrid clinical trials

Decentralised and hybrid clinical trials have been prevalent for years, yet sponsors have struggled to execute these patient-centric trials effectively.  Explore the perceived barriers and how you can make these models a feasible option for the future.

 

Read the whitepaper
The patient perspective - decentralised and hybrid trials

The patient perspective - decentralised and hybrid trials

What does the patient want? In 2019, ICON conducted a web-based survey through its global research site network, Accellacare, to get the patient view and learn whether bringing the trial to the patient makes a difference in accessing more patients. With over 4,000 patient responses, we explore perceptions and preferences around what makes it easier for patients to participate in clinical trials and to determine whether industry perception was reality.

Read the report
Advancing digital endpoints

Advancing digital endpoints

Although mHealth devices and sensors are continuing to evolve, and it is now possible to capture a vast array of physiological data, the operationalisation of digital trials is not without challenges. Navigate the shift from traditional trial models to agile, patient-centric processes driven by digital health technologies.

Read the whitepaper
Agile clinical monitoring

Agile clinical monitoring

During COVID-19 the levels of remote monitoring increased due to site closures and safety reasons. Now is the time to learn from that experience and review whether a hybrid model of remote monitoring and centralised monitoring is the way forward for some trials. Learn best practices in analysing and assessing risk in clinical monitoring and how to remain agile adapting to environmental conditions and therapeutic focus.

Read the whitepaper

What’s happening in ICON